Beam Therapeutics (BEAM) EBITDA Margin (2019 - 2026)
Beam Therapeutics (BEAM) reported EBITDA Margin of 304.05% for Q1 2026, up 115310.0% year-over-year from N/an in Q1 2025, and down 241.83% quarter-over-quarter from 214.37% in Q4 2025.
Beam Therapeutics (BEAM) EBITDA Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of EBITDA Margin data on file, last reported at 304.05% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 304.05%, up 115310.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 40.41% (up 56566.0% YoY), and the FY2025 annual result was 56.93%, up 53608.0% from the prior year.
- EBITDA Margin retreated to 304.05% in Q1 2026 per BEAM's latest filing, from 214.37% in the prior quarter.
- Over five years, EBITDA Margin peaked at 214.37% in Q4 2025 and troughed at 1457.15% in Q1 2025.
- A 5-year average of 617.19% and a median of 558.93% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin jumped 335873095 bps in 2022, then slumped 96056 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 180.19% in 2022, then jumped by 126 bps to 45.99% in 2023, then slumped by 761 bps to 304.1% in 2024, then soared by 170 bps to 214.37% in 2025, then sank by 242 bps to 304.05% in 2026.
- Business Quant data shows BEAM's EBITDA Margin at 304.05% in Q1 2026, 214.37% in Q4 2025, and 1154.34% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - | -304.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -304.05% |
| Dec 31, 2025 | 214.37% |
| Sep 30, 2025 | -1,154.34% |
| Jun 30, 2025 | -1,210.03% |
| Mar 31, 2025 | -1,457.15% |
| Dec 31, 2024 | -304.10% |
| Sep 30, 2024 | -657.36% |
| Jun 30, 2024 | -775.06% |
| Mar 31, 2024 | -1,352.15% |
| Dec 31, 2023 | 45.99% |
| Sep 30, 2023 | -558.93% |
| Jun 30, 2023 | -417.71% |
| Mar 31, 2023 | -391.59% |
| Dec 31, 2022 | -180.19% |
| Sep 30, 2022 | -696.62% |
| Jun 30, 2022 | -440.97% |
| Mar 31, 2022 | -852.38% |
| Dec 31, 2021 | -126.84% |
| Sep 30, 2021 | -3,686.76% |
| Jun 30, 2021 | -1,269,966.67% |